T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2676
Carter Bankshares
CARE
$757M
| $272K | ﹤0.01% |
13,791
+1,695
| +14% | +$31.6K |
|
2677
8x8 Inc
EGHT
$303M
| $272K | ﹤0.01% |
137,891
+15,237
| +12% | +$30K |
|
2678
Peoples Financial Services
PFIS
$717M
| $272K | ﹤0.01% |
5,573
+637
| +13% | +$30.8K |
|
2679
Arteris
AIP
$1.36B
| $271K | ﹤0.01% |
17,453
+2,955
| +20% | +$42.8K |
|
|
CHCT
2680
Community Healthcare Trust
CHCT
$433M
| $271K | ﹤0.01% |
16,452
-10,273
| -38% | -$153K |
|
2681
Grindr
GRND
$2.74B
| $271K | ﹤0.01% |
20,011
+2,481
| +14% | +$33.7K |
|
|
NXDR
2682
Nextdoor Holdings
NXDR
$998M
| $270K | ﹤0.01% |
128,173
+15,890
| +14% | +$31.1K |
|
2683
SLR Investment Corp
SLRC
$711M
| $269K | ﹤0.01% |
+17,342
| New | +$264K |
|
2684
Stoneridge
SRI
$201M
| $269K | ﹤0.01% |
46,429
| – | – |
|
2685
Weave Communications
WEAV
$426M
| $268K | ﹤0.01% |
35,255
+4,250
| +14% | +$28.2K |
|
|
FRGE
2686
DELISTED
Forge Global Holdings
FRGE
| $267K | ﹤0.01% |
+5,984
| New | +$202K |
|
2687
ATN International
ATNI
$491M
| $266K | ﹤0.01% |
11,664
-1,300
| -10% | -$24.1K |
|
2688
Bumble
BMBL
$359M
| $266K | ﹤0.01% |
74,413
| – | – |
|
2689
eHealth
EHTH
$38.8M
| $266K | ﹤0.01% |
57,736
+14,800
| +34% | +$65.2K |
|
2690
KVH Industries
KVHI
$143M
| $264K | ﹤0.01% |
37,763
| – | – |
|
2691
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
$1.58B
| $263K | ﹤0.01% |
+7,999
| New | +$262K |
|
2692
ASP Isotopes
ASPI
$539M
| $263K | ﹤0.01% |
49,044
-998,714
| -95% | -$7.94M |
|
2693
Corvus Pharmaceuticals
CRVS
$1.27B
| $263K | ﹤0.01% |
34,105
+1,696
| +5% | +$13.4K |
|
2694
RGC Resources
RGCO
$226M
| $263K | ﹤0.01% |
12,318
| – | – |
|
2695
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$23.5B
| $263K | ﹤0.01% |
2,200
| – | – |
|
2696
Groupon
GRPN
$894M
| $262K | ﹤0.01% |
14,850
+1,687
| +13% | +$31.8K |
|
2697
Midland States Bancorp
MSBI
$698M
| $262K | ﹤0.01% |
12,334
+1,403
| +13% | +$24.8K |
|
2698
Real Brokerage
REAX
$523M
| $262K | ﹤0.01% |
71,543
+13,116
| +22% | +$50.7K |
|
2699
International Money Express
IMXI
$353M
| $261K | ﹤0.01% |
16,949
+2,083
| +14% | +$31.3K |
|
|
PSIX
2700
Power Solutions International
PSIX
$947M
| $261K | ﹤0.01% |
4,554
+1,083
| +31% | +$77.3K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.